This site is intended for health professionals only

Actavis launches new prostate drug


American pharmaceutical company Actavis has begun shipping its new prostate drug Tamsulosin.

The product, a generic version of Flomax, is used to treat benign prostatic hyperplasia – also known as an enlarged prostate.

The launch, a joint venture with Synthon Pharmaceuticals, will see the product offered in 0.4mg capsules.

Actavis, a subsidiary of the Actavis Group, is based in Morristown, New Jersey. It has US manufacturing facilities across the state and in Florida, along with a packaging facility in Totowa.

The firm is one of the world’s leading generic pharmaceutical companies, specialising in the development, manufacture and sale of generic pharmaceuticals. It has operations in 40 countries, with more than 10,500 employees.

Copyright Press Association 2010

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine